Related Experiment Video

Updated: Jun 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity

S Corradini1, M Maksimos2, F Azab2

  • 1Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK.

Leukemia
|June 16, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.

Journal of medicinal chemistry·2026

A Direct-to-Biology Amine-Acid Amination for Rapid Phenotypic Profiling of Lysosomotropic Natural Products.

Journal of the American Chemical Society·2026

When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.

Cancers·2026

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

Journal of medicinal chemistry·2026

Dental Educators' Perceptions of Factors Contributing to Their Well-being-A Qualitative Study.

European journal of dental education : official journal of the Association for Dental Education in Europe·2026

Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies.

Leukemia·2026

Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML.

Leukemia·2026

Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study.

Leukemia·2026

RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly.

Leukemia·2026

Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin.

Leukemia·2026

Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.

Leukemia·2026

Albuminuria is associated with higher turnover-related bone histomorphometric indices in chronic kidney disease stages 3-4.

Clinical kidney journal·2026

The Expanding Role of Carbohydrate Antigen 125 in Heart Failure: From Tumour Marker to a Cornerstone of Heart Failure Management. An Updated Narrative Review.

Cardiac failure review·2026

Echocardiography-based multimodal models for thromboembolic risk prediction in atrial fibrillation: a narrative review.

Journal of thoracic disease·2026

Coexistence of Ebstein Anomaly and Cerebral Cavernous Malformation: A Case Report.

Clinical case reports·2026

Achieved systolic blood pressure and cardiovascular outcomes in advanced chronic kidney disease.

Clinical kidney journal·2026

Multimodal MRI to elucidate cross-organ coupling mechanisms of the heart-brain axis.

Frontiers in cardiovascular medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us